explore -WSS

explore

author：entertainment 2025-09-30 18:16:41 - browse：66384

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

WSS

EU regulator recommends expanding Mounjaro approval to obesity

The UK government moves asylum

The UK government moves asylum

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Why workplace violence is so common in health care

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

explore

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Biotech venture capitalists face new demands from investors

Activists slam private health insurers over coverage restrictions

Think you might have Covid

Medicare details structure of new drug price negotiation program

The tragedy of Johnson & Johnson’s Covid vaccine

After affirmative action ruling, medical educators look to 'holistic review'

How digital therapeutics firms are pivoting after Pear's bankruptcy

Medical records are filled with copy

Eli Lilly, Pfizer, and others want in on the online prescription market

knowledge

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Parkinson’s finding may lead to tests and, someday, treatments

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Copay coupons to count toward deductibles, after Biden court move

Medicare Advantage today, explained in one chart

My yearlong odyssey to get my son’s ADHD medication covered

knowledge

focus

hotspot

hotspot